Clinical Trial Update: Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure [Phase 2]

View source ↗

Summary

Phase 2 trial assessing daily oral CF101 for safety and efficacy in subjects with elevated intraocular pressure; study completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma
• Ocular Hypertension

Drugs mentioned

• CF101 (piclidenoson)

Snippet

Sponsor: Can-Fite BioPharma | Conditions: Ocular Hypertension, Glaucoma | Phase 2 | Status: COMPLETED | Results posted: 2019-05-23